Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Carl Zeiss Meditec AG is a leading medical technology company specializing in ophthalmology and microsurgery solutions. Headquartered in Jena, Germany, and founded in 1846, it operates as a subsidiary of the ZEISS Group, delivering innovative products for diagnosing and treating eye diseases such as ametropia, cataracts, glaucoma, and retinal disorders. Its Ophthalmology segment provides diagnostic tools like slit lamps, refractometers, optical coherence tomography devices, and fundus cameras, alongside surgical equipment including microscopes, biometers, phacoemulsification systems, vitrectomy devices, intraocular lenses, and laser surgery consumables. The Microsurgery segment offers visualization and treatment solutions for neurosurgery, ear-nose-throat procedures, spine, plastic and reconstructive surgery, and dentistry. With a global presence across Europe, North America, and Asia, employing over 5,700 people, Carl Zeiss Meditec AG drives advancements in healthcare through cutting-edge technologies, digital workflow solutions, and AI-integrated systems, enhancing clinical efficiency and patient outcomes in advanced medical equipment sectors.
10.02% operating margin is respectable but not wide. ROIC at 7.34%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 7.8%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€2.20B
▲ +7.8% YoY
Net Income (TTM)
€122M
▼ -21.0% YoY
Op. Margin
8.91%
▲ +1.5pp YoY
ROIC
7.34%
▲ +1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€176M
▲ +40.1% YoY
Op. Cash Flow (TTM)
€216M
▼ -27.2% YoY
Net Debt
€105M
Cash & Equiv.
€27M
3Y CAGR: +5.4%
3Y CAGR: +7.9%
Continue Research